Magellan Rx reports are designed to enable our customers to address utilization promptly, improving their ability to achieve market share targets and realize projected savings opportunities. We provide comprehensive quarterly PDL reports detailing our clients’ net cost of PDL decisions. Our net cost monitoring occurs on an ongoing basis, providing regular analysis of savings from preferring brands versus their generic equivalents and the impact of the quarterly CMS rebates.
Magellan Rx staff have extensive contacts and relationships with organizations throughout the Medicaid market, including CMS, Congressional Budget Office, and trade associations. This permits us to stay connected to market developments and be in a position to offer guidance and expertise toward best practices in Medicaid.